Relationship between clinical toxicities and ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms in cervical cancer patients



Several studies have suggested that there are single nucleotide polymorphisms (SNPs) that can be considered potential biomarkers in the prognosis and therapeutic response of cancer patients. The present study investigated the association between ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms and clinical toxicities induced by chemoradiotherapy (CRT) in cervical cancer.


This hospital-based retrospective cohort study included 260 patients with cervical cancer, FIGO stages Ib2-IVa, who underwent CRT (cisplatin). Genetic polymorphisms analysis was performed by allelic discrimination with real-time polymerase chain reaction (RT-PCR).


Our results indicated a link between ERCC1 rs3212986 and the onset of late gastrointestinal toxicity (p = 0.038). Furthermore, using a recessive model (AA vs. CC/CA), we found that patients carrying AA homozygous genotype presented a fourfold increased risk of developing late gastrointestinal toxicity when compared with patients with the C allele (odds ratio = 3.727, 95% confidence interval, 1.199-11.588; p = 0.017). No association was found regarding the XRCC3 rs861539 polymorphism and any clinical toxicity event.


This is the first study evaluating the relationship between these polymorphisms and clinical toxicities in cervical cancer patients submitted to CRT with cisplatin. These results may contribute toward a better understanding of the influence of genetic polymorphisms in genes associated with DNA repair in the clinical response to CRT of patients with cervical cancer.

Post author correction




Sílvia Soares, Augusto Nogueira, Ana Coelho, Joana Assis, Deolinda Pereira, Isabel Bravo, Rui Medeiros

Article History


Financial support: This work was supported in part by the Research Center of the Portuguese Institute of Oncology of Porto, Portugal (project no. CI-IPOP-22-2015). The authors also thank the Liga Portuguesa Contra o Cancro – Centro Regional do Norte (Portuguese League Against Cancer) for the financial support.
Conflicts of interest: The authors declare they have no conflicts of interest.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.



  •  Molecular Oncology and Viral Pathology Group – Research Center, Portuguese Institute of Oncology, Porto - Portugal
  •  FMUP, Faculty of Medicine of Porto University, Porto - Portugal
  •  Research Department, Portuguese League Against Cancer (NRNorte), Porto - Portugal
  •  Oncology Department, Portuguese Institute of Oncology, Porto - Portugal
  •  Medical Physics, Radiobiology and Radioprotection Group – Research Center, Portuguese Institute of Oncology, Porto - Portugal
  •  CEBIMED, Faculty of Health Sciences of Fernando Pessoa University, Porto - Portugal
  • Sílvia Soares and Augusto Nogueira have contributed equally to this work.

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.